Shell Liang, PhD, presented “Understanding Metastatic Castration-Resistant Prostate Cancer” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Liang, Shell. “Understanding Metastatic Castration-Resistant Prostate Cancer.” September 22, 2023. Accessed Sep 2024. https://grandroundsinurology.com/understanding-metastatic-castration-resistant-prostate-cancer/
Understanding Metastatic Castration-Resistant Prostate Cancer – Summary
Shell Liang, PhD, discusses metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that progresses despite androgen deprivation therapy (ADT). Dr. Liang emphasizes the critical need for advanced therapeutic strategies to manage this aggressive cancer subtype effectively.
The presentation reviews the current therapeutic landscape for mCRPC, focusing on second-generation AR pathway inhibitors such as abiraterone and enzalutamide. Additionally, the discussion includes the role of chemotherapeutic agents like docetaxel and cabazitaxel. Dr. Liang also explores emerging treatment modalities, including PARP inhibitors and immunotherapies.
Dr. Liang advocates using genomic profiling to identify actionable mutations and tailor treatments to individual patient profiles. This approach aims to optimize therapeutic efficacy and minimize adverse effects, aligning with the principles of precision medicine.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Shell Liang is a Medical Director from US Medical Affairs at Pfizer Oncology. He is a scientific leader with broad experience in medical affairs, R&D, and commercials within the healthcare industry. With a multidisciplinary background in cell and molecular biology, immunology, biochemistry, and engineering, Shell brings extensive expertise to the field.
Shell possesses in-depth knowledge in drug discovery, clinical development, life-cycle management, companion diagnostics/IVD/LDT, genetics, and next-generation sequencing (NGS). He has a thorough understanding of regulatory and compliance requirements for the pharmaceutical, biotechnology, and diagnostic industries.
